Sudarshan Pharma Q4 FY26: Audited PAT Jumps to ₹23.3 Cr Amid GST Drama & Aggressive Asset Hunting

The pharmaceutical sector is often a game of patience and deep pockets, but Sudarshan Pharma Industries Ltd (SPIL) is currently operating at a velocity that would make a Formula 1 pit crew look slow. The company just released its audited FY26 results, and the numbers tell a story of a trading powerhouse desperately trying to transform into a high-margin manufacturing beast.

With a market cap of ₹728 Cr, this is a classic SME-to-Mainboard transition story in the making. The company is juggling multiple balls: a major GST search and seizure, the acquisition of Srigen Lifesciences, PLI scheme approvals for critical APIs like Vitamin B1 and B6, and a massive ₹1,500 Cr fundraising plan. While the revenue has crossed the ₹703 Cr mark, the real question is whether the “asset-light” trading past is finally giving way to a concrete manufacturing future.

1. At a Glance – A High-Stakes Transformation

Sudarshan Pharma is currently in the middle of a massive identity shift. For years, it was known primarily as a trader of chemicals and solvents—a low-margin, high-volume game. However, the latest financials and management actions suggest they are done playing second fiddle.

The company has reported a Net Profit of ₹23.3 Cr for FY26, up from ₹16 Cr in the previous year. But don’t let the bottom line distract you from the capital expenditure. SPIL is aggressively moving into the Active Pharmaceutical Ingredients (API) space, specifically targeting products currently imported from China. They’ve secured PLI (Production Linked Incentive) approvals for Vitamin B6 and B1, with a combined maximum incentive of ₹115 Cr.

However, it hasn’t been all smooth sailing. In February 2026, the company’s registered office was visited by the GST department for “inspection, search, and seizure.” While management says operations are unaffected, such headlines usually keep conservative investors awake at night. Combine this with the resignation of the long-standing CFO (who happens to be the Joint MD) and the appointment of new blood, and you have a corporate drama that is as intriguing as its financial growth.

2. Introduction

Incorporated in 2008, Sudarshan Pharma started its journey in the trenches of chemical trading. Over the last decade and a half, it has built a massive distribution network, catering to heavyweights like Reliance, DuPont, and Sun Pharma.

The company operates through three main verticals:

• Specialty Chemicals: Trading and distribution of high-demand solvents.
• API & Intermediates: The new growth engine focused on import substitution.
• Generic Formulations: Branded and unbranded medicines for domestic and export markets.

With a recent 1:10 stock split and a global expansion strategy spanning from Dubai to Canada, SPIL is positioning itself as a vertically integrated pharma player.

3. Business Model – WTF Do They Even Do?

Imagine a middleman who suddenly decides he wants to own the factory. That’s SPIL.

1. The Trading Legacy: They buy chemicals like Acetonitrile and Tetrahydrofuran (THF) in bulk and sell them to industries ranging from paints to adhesives. It’s a volume game with 7.30% OPM, which is thin but provides the cash flow to fund bigger dreams.
2. The Manufacturing Pivot: They are setting up units to manufacture APIs that India currently begs China for. The Palghar Unit 2 is already operational, producing oral liquids and formulations.
3. The Brand Game: They have 56 products under registered trademarks like Love Birds and Heart Kit. Yes, “Love Birds”—because nothing says pharmaceutical excellence like a name that sounds like a 90s rom-com.

4. Financials Overview – Walking the Talk?

Analysis:

The Q4 FY26 performance was a significant outlier. Management previously spoke about margin optimization, and the jump in PAT from ₹4 Cr in Q3 to ₹11 Cr in Q4 suggests that the higher-margin manufacturing sales are finally kicking in. However, the Interest costs have ballooned to ₹8 Cr in the latest quarter compared to ₹4 Cr a year ago. The debt is feeding the growth, but it’s getting expensive.

Does management walk the talk? They promised vertical integration and acquisitions. With the Srigen Lifesciences deal and the Dubai Cibachem buyout, they are certainly moving the chess pieces, even if the GST department is trying to checkmate them.

5. Valuation Discussion – Fair Value Range

All calculations are based on the latest consolidated data.

Method 1: P/E Multiple

• Current EPS: ₹0.97
• Industry Median P/E: 28.9
• Target Value = $0.97 \times 28.9 = ₹28.03$

Method 2: EV/EBITDA

• Current EBITDA: ₹51 Cr
• Enterprise Value: ₹1,012 Cr
• EV/EBITDA Ratio: 19.8
• Applying an industry-standard 15x multiple to ₹51 Cr EBITDA gives an EV of ₹765 Cr. Subtracting Debt (₹285 Cr)